Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

CERo Therapeutics (CERO) announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office, USPTO, which ...

The persistence of a similar TCR repertoire at postoperative endoscopy was associated with smoking and disease recurrence. Patients with high clonality showed increased expression of genes associated ...

Engineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education), Hunan Key Laboratory of Pharmacomicrobiomics, Department of Clinical Pharmacology, Xiangya Hospital, ...

第34届亚太肝病学会年会（APASL ...

Investing.com — CERo Therapeutics Holdings, Inc. (NASDAQ: CERO )，一家专注于工程化T细胞免疫疗法的公司，目前市值为160万美元，宣布美国专利商标局 (USPTO)已批准其两项关键专利申请，标志着其知识产权的显著扩展。根据 InvestingPro ...

该研究首次解析了柑橘抗黄龙病的核心分子机制，阐明了由 PUB21-MYC2 组成的黄龙病抗性遗传回路，并利用 AI 辅助筛选出了稳定抗病蛋白 MYC2 的双 ...

Investing.com — CERo Therapeutics Holdings, Inc. (NASDAQ: CERO )，一家专注于工程化T细胞免疫疗法的公司，目前市值为160万美元，宣布美国专利商标局 (USPTO)已批准其两项重要专利申请。这些于2025年3月获得的批准，强化了该公司在其主要化合物CER-1236（一种潜在的癌症治疗方法）方面的知识产权地位。根据 ...